{"filings":[{"id":888156,"accession_number":"0001193125-26-259532","cik":1770121,"company_name":"Sana Biotechnology, Inc.","ticker":"SANA","form_type":"8-K","filed_at":"2026-06-05T20:05:18+00:00","items":["5.07"],"status":"ready","headline":"Sana Biotechnology stockholders elect three Class II directors; ratify EY as auditor","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Hans E. Bishop elected with 117,452,573 For vs 57,148,432 Withheld; 30,606,441 broker non-votes.","Robert Nelsen elected with 160,384,193 For vs 14,216,812 Withheld; 30,606,441 broker non-votes.","Alise S. Reicin, M.D. elected with 149,865,546 For vs 24,735,459 Withheld; 30,606,441 broker non-votes.","Ratification of Ernst & Young LLP as independent auditor for FY2026: 203,932,500 For, 831,419 Against, 443,527 Abstain.","All director terms expire at 2029 annual meeting; no changes to board composition."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":851572266.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":470717,"accession_number":"0001193125-26-226674","cik":1770121,"company_name":"Sana Biotechnology, Inc.","ticker":"SANA","form_type":"8-K","filed_at":"2026-05-15T20:06:25+00:00","items":["8.01"],"status":"ready","headline":"Sana Biotechnology sells 21.6M shares for $69M in at-the-market offering","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sold 21,607,878 shares for net proceeds of approx. $69.0 million on May 15, 2026.","Equity sale conducted under amended and restated sales agreement with TD Securities as agent.","Offering utilized existing at-the-market facility; no new registration statement filed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":851572266.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":13003,"accession_number":"0001193125-26-216758","cik":1770121,"company_name":"Sana Biotechnology, Inc.","ticker":"SANA","form_type":"8-K","filed_at":"2026-05-11T20:08:24+00:00","items":["2.02","9.01"],"status":"ready","headline":"Sana Q1 net loss $47.2M, cash $101.1M; Mayo $25M equity; SC451/SG293 trials on track for 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $47.2M ($0.17/sh); R&D expenses $28.7M (down from $37.2M YoY).","Cash & securities $101.1M; pro forma $128.9M including Mayo $25M equity and ATM activity.","Mayo collaboration to accelerate SC451; Mayo made $25M equity investment with option for another $25M.","SC451 Phase 1 IND filing expected later this year; SG293 clinical data presented May 12 at ASGCT.","SG227 (BCMA CAR) expected to begin clinical testing as early as mid-2027, contingent on SG293 data."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.17,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":851572266.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95318,"accession_number":"0001193125-26-174531","cik":1770121,"company_name":"Sana Biotechnology, Inc.","ticker":"SANA","form_type":"8-K","filed_at":"2026-04-24T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Sana Biotechnology reclassifies director Steven D. Harr from Class I to Class III to balance board classes","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Director Steven D. Harr resigned as Class I director and was reappointed as Class III director effective April 22, 2026.","Change made solely to achieve equal board-class balance per certificate of incorporation.","Board now has three directors in each of Class I, II, and III."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.05,"calibrated_materiality_score":0.05,"market_cap_usd":851572266.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95317,"accession_number":"0001193125-26-152868","cik":1770121,"company_name":"Sana Biotechnology, Inc.","ticker":"SANA","form_type":"8-K","filed_at":"2026-04-13T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Sana Biotechnology sells $25M in stock to Mayo Clinic with option for additional $25M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued 7,507,507 shares at $3.33 each to Mayo Clinic for ~$25M gross proceeds; closing expected April 15, 2026.","Mayo Clinic can purchase another 7,507,507 shares at same price by Aug 31, 2026, for ~$25M additional.","Net proceeds to fund development of SC451 and genetically modified stem-cell derived islet cell products under new license agreement.","Mayo Clinic subject to 6-month lock-up from initial closing (or 3 months from second closing if elected).","Cash of $138.4M (Dec 31, 2025) plus ~$24.9M net from initial closing expected to fund operations into 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":851572266.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108269,"accession_number":"0001193125-26-088203","cik":1770121,"company_name":"Sana Biotechnology, Inc.","ticker":"SANA","form_type":"8-K","filed_at":"2026-03-03T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Sana Q4 net loss $58.8M; UP421 islet cells function at 1 year no immunosuppression; new $150M ATM filed","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["UP421 hypoimmune islet cells in type 1 diabetes show C-peptide production, immune evasion at 1 year without immunosuppression.","Expect to file IND for SC451 (stem cell-derived islet therapy) and begin Phase 1 trial this year.","SG293 in vivo CAR T: NHP data show deep B-cell depletion; first-in-human data expected this year.","Q4 2025 net loss $58.8M ($0.21/shr); R&D $34.9M; cash $138.4M; runway into late 2026.","Entered new ATM agreement with TD Cowen for up to $150M; raised $133.7M gross from equity in 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":851572266.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108268,"accession_number":"0001193125-26-053294","cik":1770121,"company_name":"Sana Biotechnology, Inc.","ticker":"SANA","form_type":"8-K","filed_at":"2026-02-17T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Sana Biotechnology appoints Brian Piper as EVP, CFO; base salary $515K, option grant of 900K shares","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Brian Piper appointed EVP, CFO and Treasurer effective February 17, 2026; replaces Steven Harr as acting principal financial officer.","Annual base salary of $515,000 with target bonus of 40% of base salary.","Granted option to purchase 900,000 shares (25% vest year 1, then monthly) and 200,000 RSUs (4-yr annual vest).","Piper previously CFO at Scorpion Therapeutics, Antares Therapeutics, and Prelude Therapeutics; over 25 years biopharma finance experience.","Company expects initial clinical data for SC451 (type 1 diabetes) and SG293 (B-cell disease) in next 12-18 months."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":851572266.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108267,"accession_number":"0001193125-26-012664","cik":1770121,"company_name":"Sana Biotechnology, Inc.","ticker":"SANA","form_type":"8-K","filed_at":"2026-01-14T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Sana: UP421 survives 12 months in T1D with no immunosuppression; plans SC451 IND, SG293 data in 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["UP421, a hypoimmune pancreatic islet cell therapy, continued to survive and function at 12 months post-transplant in a T1D patient with no immunosuppression.","On track to file an IND and begin Phase 1 trial for SC451, an iPSC-derived islet cell therapy, as early as 2026.","Goal to generate initial human data in 2026 for SG293, an in vivo CD19-directed CAR T cell therapy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":851572266.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124718,"accession_number":"0001193125-25-269522","cik":1770121,"company_name":"Sana Biotechnology, Inc.","ticker":"SANA","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Sana Q3 net loss $42.2M; shifts focus to type 1 diabetes and in vivo CAR T, suspends allogeneic CAR T","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 net loss $42.2M ($0.16/share); cash $153.1M; raised $115.8M in Q3, pro forma cash $170.5M.","Prioritizing SC451 (type 1 diabetes) IND as early as 2026 and SG293 in vivo CAR T IND as early as 2027.","Suspended allogeneic CAR T programs SC291 and SC262; NEJM published positive 12-week data for UP421 showing insulin production without immunosuppression.","Non-GAAP operating cash burn $108M for 9 months; non-GAAP net loss $39M for Q3."],"consensus_eps_estimate":-0.1835,"consensus_eps_actual":-0.75,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":851572266.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141421,"accession_number":"0001193125-25-196414","cik":1770121,"company_name":"Sana Biotechnology, Inc.","ticker":"SANA","form_type":"8-K","filed_at":"2025-09-05T23:59:59+00:00","items":["5.02","8.01"],"status":"ready","headline":"Sana Biotechnology GC Bernard Cassidy to retire Oct 20; Aaron Grossman named successor","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Bernard Cassidy will retire as EVP, General Counsel, effective Oct 20, 2025.","Aaron Grossman appointed EVP, Chief Legal Officer, starting Oct 20, 2025.","Cassidy's retirement is voluntary for personal reasons; no disagreement with Company.","Cassidy expected to provide transition services after retirement date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":851572266.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141420,"accession_number":"0001193125-25-192766","cik":1770121,"company_name":"Sana Biotechnology, Inc.","ticker":"SANA","form_type":"8-K","filed_at":"2025-08-29T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Sana Biotechnology director Mary Agnes Wilderotter resigns effective Aug 29","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Mary Agnes Wilderotter resigned as director and chair of Nominating and Corporate Governance Committee, effective Aug 29, 2025.","She also resigned from the Audit Committee. Resignation not due to any disagreement with Sana's operations, policies, or practices.","No replacement or further board changes announced in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":851572266.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141419,"accession_number":"0001770121-25-000009","cik":1770121,"company_name":"Sana Biotechnology, Inc.","ticker":"SANA","form_type":"8-K","filed_at":"2025-08-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Sana Biotechnology Q2 loss $0.39/sh (GAAP); positive type 1 diabetes cell therapy data; raises $105M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $93.8M ($0.39/sh GAAP); non-GAAP net loss $38.9M ($0.16/sh) vs $74.2M ($0.32/sh) year ago.","Cash, cash equivalents & securities $72.7M at June 30; pro forma $177.2M including $105M raised in July/August 2025.","Six-month data show transplanted HIP-edited islet cells survive & function (C-peptide+) without immunosuppression; NEJM published 12-week results.","Expect to file IND for SC451 (iPSC-derived islet cell therapy) as early as 2026; FDA INTERACT meeting supports GMP master cell bank.","Enrolling GLEAM (SC291 in autoimmune) & VIVID (SC262 in B-cell malignancies); data expected 2025; IND for SG299 in vivo CAR T as early as 2026."],"consensus_eps_estimate":-0.211,"consensus_eps_actual":-0.6,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":851572266.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141418,"accession_number":"0001193125-25-175571","cik":1770121,"company_name":"Sana Biotechnology, Inc.","ticker":"SANA","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Sana Biotechnology prices $75M public offering of common stock and pre-funded warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Priced 20,895,522 shares at $3.35/share and 1,492,537 pre-funded warrants at $3.3499/underlying share.","Gross proceeds expected ~$75M, net proceeds ~$70M after underwriting discounts and expenses.","Underwriters granted 30-day option to purchase up to 3,358,208 additional shares.","Offering expected to close August 8, 2025; Morgan Stanley, Goldman Sachs, BofA, TD Cowen lead."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":851572266.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141417,"accession_number":"0001193125-25-174506","cik":1770121,"company_name":"Sana Biotechnology, Inc.","ticker":"SANA","form_type":"8-K","filed_at":"2025-08-06T23:59:59+00:00","items":["2.02","8.01"],"status":"ready","headline":"Sana reports $90.1M cash, $40-45M facility impairment; positive UP421 data at 6 months","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Cash, cash equivalents and marketable securities ~$90.1M as of July 31, 2025.","Expects $40-45M non-cash impairment on Bothell/Seattle facilities due to sublease plans and manufacturing shift.","Raised $29.1M net proceeds via ATM sale of 7.44M shares between April 1 and August 6, 2025.","UP421 trial meets all endpoints: transplanted beta cells survive, produce insulin, evade immune detection at 6 months.","Sonja Schrepfer, SVP and Head of Hypoimmune Platform, resigned to pursue other opportunities."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":851572266.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159222,"accession_number":"0000950170-25-088752","cik":1770121,"company_name":"Sana Biotechnology, Inc.","ticker":"SANA","form_type":"8-K","filed_at":"2025-06-23T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Sana reports positive six-month data for islet cell therapy in type 1 diabetes without immunosuppression","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Six-month results: transplanted allogeneic islet cells (UP421) safe, survive, evade immune system, produce insulin without immunosuppression.","C-peptide detectable fasting and increases with mixed meal tolerance test, confirming insulin secretion; MRI shows graft survival at 6 months.","No safety issues; HIP-modified cells evade both allogeneic and autoimmune responses in type 1 diabetes patient.","Sana plans to file IND for SC451 (stem cell-derived HIP islet therapy) as soon as next year, incorporating UP421 learnings.","Data presented at ADA 85th Scientific Sessions; study funded by Helmsley Charitable Trust, partnership with Uppsala University Hospital."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":851572266.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159221,"accession_number":"0000950170-25-083044","cik":1770121,"company_name":"Sana Biotechnology, Inc.","ticker":"SANA","form_type":"8-K","filed_at":"2025-06-06T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Sana Biotechnology shareholders elect all four director nominees and ratify auditor","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All four Class I directors elected: Steven D. Harr (147.9M for), Robert L. Rosiello (158.2M for), Michelle Seitz (147.9M for), Patrick Y. Yang (143.7M for).","Ratification of Ernst & Young as independent auditor for FY2025: 180.2M for, 55.8K against, 69.6K abstain.","Broker non-votes of 20.9M shares on director election."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":851572266.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159220,"accession_number":"0000950170-25-066933","cik":1770121,"company_name":"Sana Biotechnology, Inc.","ticker":"SANA","form_type":"8-K","filed_at":"2025-05-08T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Sana reports Q1 net loss $49.4M, cash runway into 2026; new $119M ATM facility","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $49.4M ($0.21/share) vs $107.5M ($0.49/share) in Q1 2024; loss narrowed.","Cash $104.7M at Mar 31, 2025, down from $152.5M; non-GAAP cash burn $46.6M; runway into 2026.","Positive 12-week data for UP421 (HIP islet cells) in T1D: C-peptide production, immune evasion without immunosuppression.","Enrolling GLEAM (autoimmune) and VIVID (B-cell malignancies) trials; expect data in 2025.","New at-the-market (ATM) agreement with TD Cowen to sell up to $119M of common stock."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.21,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":851572266.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177663,"accession_number":"0000950170-25-040241","cik":1770121,"company_name":"Sana Biotechnology, Inc.","ticker":"SANA","form_type":"8-K","filed_at":"2025-03-17T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Sana reports Q4 net loss $49.1M; positive T1D islet cell data at 12 weeks","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["HIP-modified islet cells (UP421) produced C-peptide and MMTT response at 12 weeks without immunosuppression; no safety issues.","Cash $152.5M at Dec 31, 2024; cash runway expected into 2026.","Net loss $49.1M in Q4 2024 vs $88.1M in Q4 2023; full year 2024 net loss $266.8M.","Enrolling GLEAM (SC291 autoimmune) and VIVID (SC262 B-cell cancers); data expected in 2025.","Appointed Dhaval Patel as CSO and Tricia Stewart as CPO."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":851572266.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177662,"accession_number":"0001193125-25-005047","cik":1770121,"company_name":"Sana Biotechnology, Inc.","ticker":"SANA","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Sana Biotechnology furnishes JPM presentation; no new details in filing","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Company presented updated corporate deck at 43rd Annual J.P. Morgan Healthcare Conference on Jan 13, 2025.","Filing includes only cover page of Exhibit 99.1; actual presentation content not provided.","No specific financial or pipeline updates can be extracted from the filing excerpt.","Presentation is furnished under Item 7.01; not filed for Exchange Act purposes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":851572266.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194383,"accession_number":"0000950170-24-123727","cik":1770121,"company_name":"Sana Biotechnology, Inc.","ticker":"SANA","form_type":"8-K","filed_at":"2024-11-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Sana Biotechnology Q3 2024 net loss $59.9M; advancing three clinical programs; cash runway into 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $59.9M ($0.25/sh) for Q3 2024 vs net income of $1.0M in Q3 2023.","Cash and equivalents $199.0M as of Sep 30, 2024; expected cash runway into 2026.","Appointed Dhaval Patel as Chief Scientific Officer; expanding focus on type 1 diabetes and B-cell autoimmune diseases.","Enrolling patients in three studies: UP421 (type 1 diabetes), GLEAM (SC291 autoimmune), VIVID (SC262 oncology); data expected in 2024/2025.","Non-GAAP operating cash burn $153.1M for first nine months 2024; strategic repositioning may increase 2024 burn above prior guidance of <$200M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.95,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":851572266.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194382,"accession_number":"0000950170-24-113524","cik":1770121,"company_name":"Sana Biotechnology, Inc.","ticker":"SANA","form_type":"8-K","filed_at":"2024-10-08T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Sana Biotechnology CFO Nathan Hardy resigns; CEO Harr named acting PFO, Susan Wyrick acting CFO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CFO Nathan Hardy resigned effective Oct 4, 2024; acting appointments made same day.","CEO Steven D. Harr appointed acting Principal Financial Officer; no compensation change.","Susan Wyrick appointed Acting CFO, Treasurer, and PAO; receives $5k/month extra, $25k bonus, 20,000 RSUs.","Wyrick previously SVP Finance; former VP Controller at Juno Therapeutics prior to Celgene acquisition."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":851572266.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210714,"accession_number":"0001193125-24-218049","cik":1770121,"company_name":"Sana Biotechnology, Inc.","ticker":"SANA","form_type":"8-K","filed_at":"2024-09-12T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"CFO Nathan Hardy resigns effective October 4, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Nathan Hardy notified resignation as EVP and CFO on September 6, 2024, effective October 4, 2024.","Resignation is voluntary for personal reasons; no disagreement with company operations or policies.","No successor has been announced; CFO duties will be assumed by interim arrangement or search process."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":851572266.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210713,"accession_number":"0000950170-24-093976","cik":1770121,"company_name":"Sana Biotechnology, Inc.","ticker":"SANA","form_type":"8-K","filed_at":"2024-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Sana Q2 net loss $50.3M ($0.21/sh); cash $251.6M; operating burn target <$200M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $50.3M ($0.21 per share), improved from $114M loss ($0.59) in Q2 2023.","Cash and equivalents $251.6M; expects 2024 operating cash burn below $200M.","Four clinical trials ongoing across seven indications; initial data expected in 2024 for SC291, SC262, and UP421.","R&D expenses decreased to $60.9M (Q2 2024) from $73.0M (Q2 2023) due to strategic repositioning.","Non-GAAP operating cash burn for H1 2024 was $104.6M vs $136.5M in H1 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.7,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":851572266.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229093,"accession_number":"0000950170-24-070603","cik":1770121,"company_name":"Sana Biotechnology, Inc.","ticker":"SANA","form_type":"8-K","filed_at":"2024-06-07T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Sana Biotechnology shareholders elect all three Class III directors and ratify EY as auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Joshua H. Bilenker, M.D. elected with ~149M votes for, ~16M withheld.","Richard Mulligan, Ph.D. elected with ~149.6M votes for, ~14.9M withheld.","Mary Agnes (Maggie) Wilderotter elected with ~144.2M votes for, ~20.3M withheld.","Ratification of Ernst & Young LLP as independent auditor for FY2024 passed with ~178.5M for, ~65K against.","Annual meeting held June 6, 2024; all proposals approved as recommended."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.05,"calibrated_materiality_score":0.05,"market_cap_usd":851572266.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229092,"accession_number":"0000950170-24-055673","cik":1770121,"company_name":"Sana Biotechnology, Inc.","ticker":"SANA","form_type":"8-K","filed_at":"2024-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Sana Q1 net loss $107.5M; cash $311M after $189.8M financing; four trials on track for 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss GAAP $107.5M ($0.49/share) vs $82.1M ($0.43) YoY; adjusted net loss $69.5M ($0.32).","Cash, equivalents & securities $311.1M (Dec 2023: $205.2M); boosted by $189.8M gross equity offering in Feb 2024.","Non-GAAP operating cash burn $58.7M in Q1 vs $74.8M YoY; full-year 2024 cash burn guided below $200M.","Four ongoing clinical programs (SC291, SC262, UP421) across seven indications; initial data expected throughout 2024.","R&D expenses $56.4M, down 16% from $67.2M, reflecting 2023 strategic repositioning and headcount reduction."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.49,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":851572266.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229091,"accession_number":"0001193125-24-100902","cik":1770121,"company_name":"Sana Biotechnology, Inc.","ticker":"SANA","form_type":"8-K","filed_at":"2024-04-18T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Sana Biotechnology R&D President Douglas Williams resigns effective April 18, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Douglas Williams, Ph.D., resigned as EVP and President, Research and Development.","Resignation effective April 18, 2024; voluntary for personal reasons.","No disagreement with the company cited; no successor named.","Williams' departure removes a key R&D leader in a biotech with no pipeline-stage products."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":851572266.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":247694,"accession_number":"0000950170-24-023083","cik":1770121,"company_name":"Sana Biotechnology, Inc.","ticker":"SANA","form_type":"8-K","filed_at":"2024-02-29T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Sana Biotechnology reports Q4 net loss $88.1M; cash $205M; raises $190M in Feb; 40-60 patients in 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2023 net loss $88.1M ($0.45/share); full year net loss $283.3M ($1.46/share).","Cash $205.2M at Dec 31, 2023; Feb 2024 offering raised $189.8M gross proceeds to fund pipeline.","Plans to treat 40-60 patients in 2024 across 4 trials in oncology, autoimmune, and type 1 diabetes.","Early SC291 data safe, immune evasion, early efficacy; IND cleared for SC291 in autoimmune and SC262 in B-cell malignancies.","Appointed Doug Williams President R&D, Gary Meininger CMO; expects 2024 operating burn <$200M."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.46,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":851572266.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":247693,"accession_number":"0001193125-24-028506","cik":1770121,"company_name":"Sana Biotechnology, Inc.","ticker":"SANA","form_type":"8-K","filed_at":"2024-02-08T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Sana Biotechnology prices upsized $165M public offering of common stock and pre-funded warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sold 17.3M shares at $5.50 and pre-funded warrants for 12.7M shares at $5.4999 each.","Gross proceeds ~$165M; net proceeds ~$156.6M after underwriting discounts and expenses.","Underwriters granted 30-day option to purchase additional 4.5M shares.","Offering expected to close February 12, 2024; Morgan Stanley, J.P. Morgan, Goldman Sachs, BofA are joint book-runners."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":851572266.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":247692,"accession_number":"0001193125-24-026692","cik":1770121,"company_name":"Sana Biotechnology, Inc.","ticker":"SANA","form_type":"8-K","filed_at":"2024-02-07T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Sana reports SC291 ARDENT interim data with responses and immune evasion; cash $205.4M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Preliminary cash, cash equivalents and marketable securities as of Jan 2, 2024: approximately $205.4 million.","ARDENT interim: 4 evaluable patients; 3 partial responses including ongoing complete responses; no DLTs, GVHD, or CRS/ICANS.","HIP-edited CAR T cells evaded innate and adaptive immune responses in all 4 evaluable patients; non-HIP cells were recognized.","IND cleared for GLEAM (lupus/vasculitis) and VIVID (CD22 CAR T) trials; data expected in 2024.","Preclinical: HIP primary islets in diabetic NHP achieved insulin independence for 6 months without immunosuppression; IST of UP421 authorized."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":851572266.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":247691,"accession_number":"0001193125-24-004910","cik":1770121,"company_name":"Sana Biotechnology, Inc.","ticker":"SANA","form_type":"8-K","filed_at":"2024-01-09T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Sana presents corporate update at J.P. Morgan Healthcare Conference; details not in filing text","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Corporate presentation furnished as Exhibit 99.1 for the 42nd Annual J.P. Morgan Healthcare Conference on Jan 9, 2024.","No specific financial results, pipeline data, or guidance included in the 8-K filing text.","Company states no admission of materiality for the furnished information."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":851572266.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":265142,"accession_number":"0001193125-23-292542","cik":1770121,"company_name":"Sana Biotechnology, Inc.","ticker":"SANA","form_type":"8-K","filed_at":"2023-12-11T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Sana Biotechnology releases updated corporate deck; no specific material changes disclosed in filing text","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Filing references an updated corporate presentation as Exhibit 99.1, but no content from the deck is provided in the exhibit text.","No financial results, pipeline milestones, guidance changes, or strategic updates are reported.","Presentation date is December 2023; no quantitative data or new clinical timelines available.","The filing is a routine Regulation FD disclosure with forward-looking statements and risk factors only.","Investors would need to review the full presentation separately for any material updates."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":851572266.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":265141,"accession_number":"0000950170-23-061130","cik":1770121,"company_name":"Sana Biotechnology, Inc.","ticker":"SANA","form_type":"8-K","filed_at":"2023-11-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Sana Biotechnology Q3 2023 GAAP net income $1.0M; cash $268.6M, pipeline data expected 2023-2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 2023 GAAP net income $1.0M driven by $82.6M gain from fair value changes on success payment liabilities.","Cash position $268.6M; expects 2024 operating cash burn below $200M, runway into 2025.","Phase 1 ARDENT trial for SC291 (CD19-directed CAR T) enrolling; initial data expected 2023, more robust in 2024.","CTA submitted for IST of HIP-modified primary islet cells in type 1 diabetes; data expected 2023 and 2024.","IND submitted for SC291 in B-cell autoimmune diseases; SC262 IND on track for 4Q 2023; data expected 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.01,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":851572266.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":265140,"accession_number":"0001193125-23-253493","cik":1770121,"company_name":"Sana Biotechnology, Inc.","ticker":"SANA","form_type":"8-K","filed_at":"2023-10-10T23:59:59+00:00","items":["2.05","7.01","9.01"],"status":"ready","headline":"Sana cuts workforce 29%, delays SG299 IND; 2024 cash burn under $200M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Workforce reduction of ~29%; expects 2024 operating cash burn below $200 million.","IND submitted for SC291 (HIP CD19 CAR T) in autoimmune diseases; initial data expected 2024.","Delaying SG299 (in vivo CAR T) IND; reducing near-term investment in fusogen platform.","SC262 (HIP CD22 CAR T) IND on track for Q4 2023; proof-of-concept data expected 2024.","HIP-modified islet cell CTA submitted for type 1 diabetes trial; data expected 2023 and 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":851572266.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":282344,"accession_number":"0000950170-23-047822","cik":1770121,"company_name":"Sana Biotechnology, Inc.","ticker":"SANA","form_type":"8-K","filed_at":"2023-09-13T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Sana Biotechnology expects to file IND for SC291 in autoimmune diseases in Q4 2023, with clinical data in 2024","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Sana expects to file investigational new drug application for SC291 in autoimmune diseases in Q4 2023.","Clinical data from SC291 in autoimmune diseases expected in 2024.","Announcement made at Morgan Stanley 21st Annual Global Healthcare Conference on September 12, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":851572266.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":282343,"accession_number":"0000950170-23-043683","cik":1770121,"company_name":"Sana Biotechnology, Inc.","ticker":"SANA","form_type":"8-K","filed_at":"2023-08-21T23:59:59+00:00","items":["1.02"],"status":"ready","headline":"Sana Biotechnology terminates Fremont lease for $3.42M; moves manufacturing to Bothell, WA","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Lease for 163,193 sq ft in Fremont, CA terminated Aug 30, 2023.","Termination fee of approximately $3.42 million paid to landlord.","Irrevocable letter of credit returned; mutual release of claims with customary exclusions.","Company will establish its planned manufacturing facility at Bothell Facility (79,565 sq ft) instead."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":851572266.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":282342,"accession_number":"0000950170-23-038002","cik":1770121,"company_name":"Sana Biotechnology, Inc.","ticker":"SANA","form_type":"8-K","filed_at":"2023-08-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Sana Q2 net loss $114M ($0.59/shr); cash $325.9M; SC291 enrollment ongoing, data expected H2 2023","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $114M in Q2 2023 vs $72.5M in Q2 2022; six-month net loss $196.1M.","Cash, cash equivalents, and marketable securities $325.9M as of June 30, 2023, expected to fund operations into 2025.","Enrolling patients in ARDENT Phase 1 trial for SC291 (CD19 CAR T) in B-cell malignancies; initial clinical data expected in H2 2023.","Plan to file IND for SC262 and SG299 in hematologic cancers and SC451 (islet cell) in type 1 diabetes in 2024.","Appointed Doug Williams as President of R&D and Gary Meininger as CMO."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.02,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":851572266.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":301520,"accession_number":"0000950170-23-027254","cik":1770121,"company_name":"Sana Biotechnology, Inc.","ticker":"SANA","form_type":"8-K","filed_at":"2023-06-09T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Sana Biotechnology 2023 annual meeting results; all director nominees elected, auditor ratified","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Hans E. Bishop elected Class II director with 108,928,064 votes for, 19,856,165 withheld.","Robert Nelsen elected Class II director with 111,403,976 votes for, 17,380,253 withheld.","Alise S. Reicin, M.D. elected Class II director with 110,664,981 votes for, 18,119,248 withheld.","Ratification of Ernst & Young as auditor for FY2023 approved: 142,770,600 for, 184,749 against, 125,243 abstain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":851572266.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":301519,"accession_number":"0000950170-23-026732","cik":1770121,"company_name":"Sana Biotechnology, Inc.","ticker":"SANA","form_type":"8-K","filed_at":"2023-06-07T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Sana Biotechnology presents corporate update at Jefferies conference; no specific data in filing","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Filed updated corporate presentation as Exhibit 99.1 for Jefferies Healthcare Conference on June 7, 2023.","No financial results, guidance changes, or pipeline milestones explicitly disclosed in the 8-K or provided exhibit.","Investors should refer to the full presentation for details on strategy and pipeline."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":851572266.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":301518,"accession_number":"0001564590-23-007072","cik":1770121,"company_name":"Sana Biotechnology, Inc.","ticker":"SANA","form_type":"8-K","filed_at":"2023-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Sana Biotechnology Q1 net loss $82.1M; advancing SC291 trial with data expected H2 2023","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash $355.1M, supports operations into 2025; non-GAAP operating cash burn $74.8M for Q1.","SC291 Phase 1 ARDENT trial enrolling; granted Fast Track for r/r large B-cell lymphoma and CLL.","Plan to file INDs for SC262 and SG299 in H2 2023; SC451 IND in 2024.","Appointed Dr. Doug Williams as President of R&D and Dr. Gary Meininger as CMO.","Net loss $82.1M ($0.43/share) vs $31.4M ($0.17) prior year; R&D expense $67.2M down 7.6%."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.43,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":851572266.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":301517,"accession_number":"0001564590-23-006600","cik":1770121,"company_name":"Sana Biotechnology, Inc.","ticker":"SANA","form_type":"8-K","filed_at":"2023-04-28T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Sana Biotechnology announces departure of Sunil Agarwal as EVP, Head of Development and CMO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Separation effective April 28, 2023; Sunil Agarwal to provide transition services under a Transition Agreement.","Severance of $560,523 (9 months base salary plus pro-rata bonus) plus COBRA coverage for up to 9 months.","Acceleration of 89,377 unvested stock options; exercise period extended to December 31, 2023.","Consulting Agreement at $256/hour, effective April 29, 2023, ending May 12 or extended to May 26, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":851572266.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":301516,"accession_number":"0001564590-23-005548","cik":1770121,"company_name":"Sana Biotechnology, Inc.","ticker":"SANA","form_type":"8-K","filed_at":"2023-04-10T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Sana appoints Douglas Williams as President of R&D and Gary Meininger as CMO; CMO Sunil Agarwal departs","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Douglas Williams, Ph.D., appointed EVP & President, R&D effective April 10, 2023; previously CEO of Codiak BioSciences.","Gary Meininger, M.D., appointed Chief Medical Officer; previously SVP, Head of Clinical Development at Vertex.","Sunil Agarwal, M.D., resigns as CMO effective April 10, 2023; will remain employee through April 28 for transition.","Williams receives $580,000 base salary, 40% target bonus, and option to purchase 1,100,000 shares of common stock."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":851572266.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":321315,"accession_number":"0001564590-23-003795","cik":1770121,"company_name":"Sana Biotechnology, Inc.","ticker":"SANA","form_type":"8-K","filed_at":"2023-03-16T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Sana reports Q4 net loss $80.4M; cash $434M; SC291 IND cleared, expects clinical data this year","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss Q4 2022 $80.4M ($0.42/sh) vs $110.7M ($0.60/sh) in Q4 2021; FY2022 net loss $269.5M ($1.43/sh).","Cash and marketable securities $434.0M at Dec 31, 2022, down from $746.9M; cash runway into 2025.","SC291 (CD19-targeted allogeneic CAR T) IND cleared; initial clinical data expected in 2023.","Plans to move manufacturing to Bothell, WA; expects ~$100M cost savings versus Fremont build-out.","Non-GAAP operating cash burn FY2022 $288.3M vs $209.6M; restructuring costs in Q4 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":851572266.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":321314,"accession_number":"0001564590-23-000832","cik":1770121,"company_name":"Sana Biotechnology, Inc.","ticker":"SANA","form_type":"8-K","filed_at":"2023-01-26T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Sana Biotechnology receives FDA IND clearance for SC291 allogeneic CAR T therapy in B-cell malignancies","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA cleared IND for SC291, a CD19-targeted allogeneic CAR T therapy using Sana's hypoimmune platform, in patients with B-cell lymphomas or leukemias.","Goal to report initial SC291 clinical data in 2023; second IND for SC262 (CD22-targeted) expected this year.","Hypoimmune platform disrupts MHC class I/II expression and overexpresses CD47 to evade immune rejection.","Preclinical data shown across models; platform also being developed for pancreatic islet cell therapy in type 1 diabetes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":851572266.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":321313,"accession_number":"0001193125-23-016245","cik":1770121,"company_name":"Sana Biotechnology, Inc.","ticker":"SANA","form_type":"8-K","filed_at":"2023-01-26T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"FDA clears Sana's IND for SC291 allogeneic CAR T therapy in B-cell malignancies","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["SC291 is a CD19-targeted allogeneic CAR T cell therapy using Sana's hypoimmune platform.","FDA clearance allows first-in-human study in patients with B-cell lymphomas and leukemias.","Company expects initial clinical data from SC291 study later in 2023.","Plans to submit a second IND this year for SC262, a CD22-targeted allogeneic CAR T therapy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":851572266.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":321312,"accession_number":"0001564590-23-000306","cik":1770121,"company_name":"Sana Biotechnology, Inc.","ticker":"SANA","form_type":"8-K","filed_at":"2023-01-10T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Sana 8-K furnishes J.P. Morgan presentation; no material new data disclosed","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Company presented updated corporate presentation at 41st Annual J.P. Morgan Healthcare Conference on Jan 10, 2023.","Presentation filed as Exhibit 99.1 but specific content (e.g., pipeline, financials) not described in 8-K.","No forward guidance or material events announced in the filing itself."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":851572266.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":339425,"accession_number":"0001193125-22-294309","cik":1770121,"company_name":"Sana Biotechnology, Inc.","ticker":"SANA","form_type":"8-K","filed_at":"2022-11-29T23:59:59+00:00","items":["2.05","9.01"],"status":"ready","headline":"Sana Biotech prioritizes pipeline, cuts 15% staff, halts SC187; maintains cash runway into 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Headcount reduced by ~15%; expects ~$7.9M in cash severance and ~$2.2M non-cash stock-based comp charges.","Discontinues internal investment in SC187 (cardiomyocytes for heart failure) to focus on core programs.","SC291 (CD19 CAR T) IND on track for 2022; initial clinical data expected in 2023.","SC263 and SG295 INDs expected in 2023; SC451 and SC255 INDs in 2024.","Cash runway extended into 2025; program timelines for lead programs not impacted."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":851572266.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":339424,"accession_number":"0001564590-22-036367","cik":1770121,"company_name":"Sana Biotechnology, Inc.","ticker":"SANA","form_type":"8-K","filed_at":"2022-11-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Sana Biotechnology reports Q3 net loss $85.1M; cash $511.6M; pipeline IND timeline updates","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $85.1M ($0.45 per share) vs $83.3M ($0.46 per share) in Q3 2021; cash, cash equivalents and marketable securities $511.6M at Sep 30, 2022.","Cash runway expected into 2025; operating cash burn $219.8M for nine months ended Sep 30, 2022.","SC291 (allogeneic CAR T) IND filing on track for 2022 with clinical data expected in 2023.","SG295 (in vivo CAR T) IND filing delayed to 2023 to incorporate second-generation process with 50X potency improvement.","SC276 IND on track for 2023; SC451 (type 1 diabetes cell therapy) IND expected in 2024 with data in 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.01,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":851572266.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":339423,"accession_number":"0001564590-22-036057","cik":1770121,"company_name":"Sana Biotechnology, Inc.","ticker":"SANA","form_type":"8-K","filed_at":"2022-11-01T23:59:59+00:00","items":["5.05"],"status":"ready","headline":"Sana Biotechnology adopts revised Code of Business Conduct and Ethics with enhanced conflict-of-interest policies","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Board adopted amended Code on October 27, 2022, adding details on potential conflicts of interest.","Revised Code includes policies and procedures for evaluating conflicts involving Board members.","No waivers granted; full text available on company's investor relations website.","Routine governance update with no financial or operational impact."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":851572266.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":356785,"accession_number":"0001564590-22-028027","cik":1770121,"company_name":"Sana Biotechnology, Inc.","ticker":"SANA","form_type":"8-K","filed_at":"2022-08-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Sana Q2 net loss $72.5M; cash runway extended into 2025 on manufacturing move savings","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash position $579.6M at June 30, 2022, down $167.3M from Dec 31, 2021.","Q2 net loss $72.5M ($0.39 per share) vs net income $18.7M in Q2 2021.","Expect cash runway into 2025; ~$100M cost savings from relocating manufacturing to Bothell, WA.","Plan to file INDs in 2022 for SC291 and SG295; SC451 (type 1 diabetes) IND in 2023.","Presented preclinical data showing survival of HIP pancreatic islet cells, cardiomyocytes, RPE cells in NHP."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.56,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":851572266.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":375256,"accession_number":"0001564590-22-023139","cik":1770121,"company_name":"Sana Biotechnology, Inc.","ticker":"SANA","form_type":"8-K","filed_at":"2022-06-14T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Sana Biotechnology presents updated corporate deck at Goldman Sachs conference","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Company discussed updated corporate presentation at Goldman Sachs 43rd Annual Global Healthcare Conference on June 14, 2022.","No specific financial or pipeline data disclosed in the filing; presentation content not fully reproduced.","Filing is a routine Reg FD disclosure; no material changes to previously announced information evident."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":851572266.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2022-06-14T23:59:59+00:00|375256"}